Genmab A/SGMABNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-2.1%
5Y CAGR+30.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-2.1%/yr
vs +88.1%/yr prior
5Y CAGR
+30.6%/yr
Recent deceleration
Acceleration
-90.2pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
3.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$2.51B-33.8%
2024$3.79B+15.0%
2023$3.30B+23.2%
2022$2.68B+108.6%
2021$1.28B+94.1%
2020$661.00M+93.3%
2019$342.00M+60.0%
2018$213.69M+45.4%
2017$146.99M+43.5%
2016$102.41M-